Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Dysgueusia.

Artykuły w czasopismach na temat „Dysgueusia”

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 18 najlepszych artykułów w czasopismach naukowych na temat „Dysgueusia”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.

1

Gouel, Pierrick, Clémence Mahana iti Gatti, Luc de Haro, Alice Liautaud, Jérôme Langrand, and Denis Boucaud-Maitre. "Tetrodotoxin Poisoning in Mainland France and French Overseas Territories: A Review of Published and Unpublished Cases." Toxins 14, no. 5 (2022): 351. http://dx.doi.org/10.3390/toxins14050351.

Pełny tekst źródła
Streszczenie:
Tetrodotoxin is one of the most potent neurotoxins in the aquatic world. This review of published and unpublished reports aims to describe the poisoning cases that have occurred in mainland France and overseas territories. Six articles were included, with 13 poisoning events, individuals or collective (number (n) = 53 patients). Moreover, 13 unpublished poisoning events from toxicovigilance networks were found (n = 17). All cases happened in overseas territories: French Guyana (n = 7), New Caledonia (n = 11), Reunion (n = 35) and French Polynesia (n = 17). The median age was 36 years. The most
Style APA, Harvard, Vancouver, ISO itp.
2

Doutrelant, Philippe, Nicolas Penel, Charlotte Renaudat, et al. "Very low seroprevalence of sars-cov-2 among health care personnel (HCP) in a French northern comprehensive cancer center at the end of first national containment." Journal of Clinical Oncology 39, no. 15_suppl (2021): e13604-e13604. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e13604.

Pełny tekst źródła
Streszczenie:
e13604 Background: To limit SARS-Co-2 transmission in general population, French government had set up a first National containment from March 16, 2020 to June 2, 2020. Furthermore, General Direction of our hospital have implemented and organized physical distancing (telework, teleconsultation, virtual multi-disciplinary board), mask wearing, use of alcoholic ... to limit interpersonal contacts. To assess the impact of this policy, we have carried out a seroprevalence study and identified risk factors for SARS-Co-2 prevalence among HCP in May/June 2020. Methods: This is part of CORSER Study (“
Style APA, Harvard, Vancouver, ISO itp.
3

Fleming, Mark T., Dana E. Rathkopf, Jackie Gibbons, et al. "Results from a phase I study of enzalutamide in combination with docetaxel in men with prostate cancer." Journal of Clinical Oncology 31, no. 15_suppl (2013): 5066. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.5066.

Pełny tekst źródła
Streszczenie:
5066 Background: Enzalutamide (ENZA) is a novel androgen receptor (AR) inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) who had received prior docetaxel (DOC). DOC also prolongs survival in mCRPC and also appears to have anti-tumor effects mediated through the androgen-receptor axis, providing a compelling rationale for combining the two agents. CYP3A4 plays a role in DOC clearance and is induced by ENZA. We therefore conducted a phase I study to explore the PK and safety profiles of this combination. Methods: This study (NCT01565928) evaluat
Style APA, Harvard, Vancouver, ISO itp.
4

Fleming, Mark T., Dana E. Rathkopf, Jackie Gibbons, et al. "Enzalutamide in combination with docetaxel in men with prostate cancer (PC): Preliminary results from a phase I study." Journal of Clinical Oncology 31, no. 6_suppl (2013): 63. http://dx.doi.org/10.1200/jco.2013.31.6_suppl.63.

Pełny tekst źródła
Streszczenie:
63 Background: Enzalutamide (ENZA), a novel oral androgen receptor (AR) inhibitor, inhibits AR signaling via inhibition of androgen binding to the AR, AR nuclear translocation, and nuclear AR-DNA binding. ENZA demonstrated a survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC) who had received prior docetaxel (Scher et al, NEJM 2012; 367:1187). A Phase III study in men with progressive chemotherapy-naïve disease (PREVAIL), is ongoing. Docetaxel (DOC) is the current standard first-line chemotherapy for mCRPC. CYP3A4, which plays a role in DOC clearance, is induce
Style APA, Harvard, Vancouver, ISO itp.
5

Boulinguez, S., M. Mularcyk, and R. Viraben. "Dysgueusie amère aux pignons de pin." Annales de Dermatologie et de Vénéréologie 141, no. 3 (2014): 220–22. http://dx.doi.org/10.1016/j.annder.2014.01.006.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Aynaou, H., F. M. O. Elilie, and H. Latrech. "Hyperparathyroïdie primaire et dysgueusie : une association inhabituelle." Annales d'Endocrinologie 77, no. 4 (2016): 442–43. http://dx.doi.org/10.1016/j.ando.2016.07.556.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Roblot, P., M. Paccalin, F. Roy-Péaud, C. Landron, L. Juhel, and B. Becq-Giraudon. "Les dysgueusies acquises : après la iatrogénie…" La Revue de Médecine Interne 22 (June 2001): 72–73. http://dx.doi.org/10.1016/s0248-8663(01)83426-3.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Ruhin-Poncet, B., A. Guerre, P. Goudot, and C. Escande. "Dysosmies et dysgueusies post-traumatiques : aspects médicolégaux." Revue de Stomatologie et de Chirurgie Maxillo-faciale 111, no. 5-6 (2010): 296–98. http://dx.doi.org/10.1016/j.stomax.2010.10.009.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Gutiérrez-Cid, Isabel, Arthur Lionnet, and Yann Péréon. "Dysphonie et dysgueusie aiguës : l’ENMG reste un élément clé du diagnostic." Neurophysiologie Clinique/Clinical Neurophysiology 46, no. 3 (2016): 225. http://dx.doi.org/10.1016/j.neucli.2016.06.020.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Cabon, M., G. Cinquetti, C. Cuvelier, et al. "Une carence de mauvais goût : à propos d’une dysgueusie révélatrice d’une carence martiale." La Revue de Médecine Interne 33 (June 2012): S96—S97. http://dx.doi.org/10.1016/j.revmed.2012.03.128.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
11

Le Moigne, M., M. Saint-Jean, A. Jirka, et al. "Dysgueusie et perte de poids sous vismodegib : intérêt d’une prise en charge nutritionnelle spécifique." Annales de Dermatologie et de Vénéréologie 140, no. 12 (2013): S392. http://dx.doi.org/10.1016/j.annder.2013.09.069.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
12

Crameri, Manuel, Renzo Bassetti, Peter Werder, and Johannes Kuttenberger. "Tonsillolithes sur l’orthopantomogramme (OPT)." SWISS DENTAL JOURNAL SSO – Science and Clinical Topics 126, no. 1 (2016): 33–36. http://dx.doi.org/10.61872/sdj-2016-01-04.

Pełny tekst źródła
Streszczenie:
La lithiase amygdalienne est caractérisée par la présence de concrétions calciques (tonsillolithes) dans les cryptes des amygdales. Le plus souvent, ces concrétions se situent dans les amygdales palatines. Leur prévalence est de 16 à 46,1%. Les tonsillolithes peuvent provoquer une mauvaise haleine chronique (halitose), une toux irritative, une dysphagie, des otalgies, des sensations de corps étranger, un mauvais goût dans la bouche (dysgueusie) ainsi que des épisodes récurrents d’amygdalite et des ulcérations de l’amygdale. Mais ces concrétions sont souvent asymptomatiques. En général, les cal
Style APA, Harvard, Vancouver, ISO itp.
13

Thieblemont, Catherine, Anastasios Stathis, Giorgio Inghirami, et al. "A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies." Blood 124, no. 21 (2014): 4417. http://dx.doi.org/10.1182/blood.v124.21.4417.4417.

Pełny tekst źródła
Streszczenie:
Abstract Rationale: BET-bromodomain (BRD) proteins are DNA readers that bind acetylated histone (H) tails preferentially at hyperacetylated superenhancer promoter regions and trigger gene transcription. The expression of several oncogenes, including c-MYC, is epigenetically regulated by BRD. OTX015 is a BRD 2, 3 and 4 inhibitor that prevents BRD binding to acetylated H4 and downregulates gene expression of BRD-dependent genes. OTX015 has been shown to inhibit the growth of diffuse large B-cell lymphoma (DLBCL) cells in vitroand in animal models. Patients & Methods: Patients with non-leukem
Style APA, Harvard, Vancouver, ISO itp.
14

Carignan, Alex, Louis Valiquette, Cynthia Grenier, et al. "Anosmie et dysgueusie associées à l’infection au SRAS-CoV-2: étude cas–témoins appariée selon l’âge." Canadian Medical Association Journal 192, no. 46 (2020): E1487—E1492. http://dx.doi.org/10.1503/cmaj.200869-f.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
15

Jirka, A., M. Saint-Jean, M. Le Moigne, et al. "P273: Dysgueusie et dénutrition au cours des traitements par le vismodegib : effet d’une prise en charge nutritionnelle." Nutrition Clinique et Métabolisme 28 (December 2014): S212. http://dx.doi.org/10.1016/s0985-0562(14)70915-x.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
16

Dombret, Hervé, Claude Preudhomme, Céline Berthon, et al. "A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia." Blood 124, no. 21 (2014): 117. http://dx.doi.org/10.1182/blood.v124.21.117.117.

Pełny tekst źródła
Streszczenie:
Abstract Rationale: BET-bromodomain (BRD) proteins play a major role in the epigenetic regulation of gene transcription, notably of genes with superenhancer promoter regions including many oncogenes, such as MYC. OTX015 is a specific BRD 2, 3 and 4 inhibitor that blocks oncogene transcription, and triggers growth inhibition and apoptosis in acute leukemia cell lines and patient cells in vitro (Braun et al. ASH Annual Meeting 2013). Based on these findings, a Phase 1 study of OTX015 was designed for patients with advanced acute leukemia. Patients & Methods: Patients with various unselected
Style APA, Harvard, Vancouver, ISO itp.
17

Chaves, Ieda Bezerra, Amanda Alves Fecury, Euzébio de Oliveira, Carla Viana Dendasck, and Claudio Alberto Gellis de Mattos Dias. "Séquelles de la COVID 19 dans le goût et l'odorat: une brève revue de la littérature." Núcleo do Conhecimento 01, no. 11 (2021): 150–66. https://doi.org/10.32749/nucleodoconhecimento.com.br/sante/sequelles-de-la-covid-19.

Pełny tekst źródła
Streszczenie:
Les virus sont un être vivant qui n'est pas formé par la structure cellulaire. Les virus peuvent être transmis par contact direct avec des personnes infectées ou indirectement à partir de surfaces contaminées. Défini comme une nouvelle variété de coronavirus, le COVID 19 a fait déclarer à l'Organisation mondiale de la santé (OMS) début 2020 une crise de santé publique mondiale. Compte tenu de la haute transmissibilité de ce virus, il était nécessaire d'adopter des mesures pour prévenir la transmission et l'infection. Les symptômes causés par la COVID-19 sont habituellement de la fièvre, de la
Style APA, Harvard, Vancouver, ISO itp.
18

Bernardor, Julie, Sacha Flammier, Sara Cabet, et al. "Intermittent Bi-Daily Sub-cutaneous Teriparatide Administration in Children With Hypoparathyroidism: A Single-Center Experience." Frontiers in Pediatrics 9 (November 8, 2021). http://dx.doi.org/10.3389/fped.2021.764040.

Pełny tekst źródła
Streszczenie:
Introduction: The use of teriparatide has been reported in children with hypoparathyroidism as an investigational physiologic replacement therapy.Methods: We aimed to retrospectively report our pediatric experience of bi-daily sub-cutaneous teriparatide. Results are presented as median (25th−75th quartile). As part of the routine follow-up of these patients with hypoparathyroidism, total calcium at H0 (i.e., just before injection) and H4 (i.e., 4 h after teriparatide injection) and other biomarker parameters were regularly assessed.Results: At a median age of 10.7 (8.1–12.6) years, an estimate
Style APA, Harvard, Vancouver, ISO itp.
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!